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Peripartum cardiomyopathy (PPCM) is a severe cardiac disease occurring in the last month
of pregnancy or in the first 5 months after delivery and shows many similar clinical
characteristics as dilated cardiomyopathy (DCM) such as ventricle dilation and systolic
dysfunction. While PPCM was believed to be DCM triggered by pregnancy, more and
more studies show important differences between these diseases. While it is likely they
share part of their pathogenesis such as increased oxidative stress and an impaired
microvasculature, discrepancies seen in disease progression and outcome indicate there
must be differences in pathogenesis as well. In this review, we compared studies in DCM
and PPCM to search for overlapping and deviating disease etiology, pathogenesis and
outcome in order to understand why these cardiomyopathies share similar clinical features
but have different underlying pathologies.
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INTRODUCTION
Peripartum cardiomyopathy (PPCM) is a cardiac disease that
can have many different clinical presentations but shares simi-
lar clinical symptoms with dilated cardiomyopathy (DCM) such
as ventricle dilation, impaired systolic function and arrhythmias
(Pearson et al., 2000; Elliott et al., 2008). Therefore, PPCM is
often seen as DCM initiated during pregnancy. However, there are
some important differences between the two cardiomyopathies
which argue for separation of the two disease states. This review
aims to compare studies performed in PPCM and DCM patients
and animal models in order to better understand why these car-
diomyopathies share similar clinical features but have different
underlying pathomechanisms.
CLINICAL PRESENTATIONS
Dilated cardiomyopathy has a variety of causes such as: genetic
factors, viral infections, alcohol abuse and myocardial infarction.
Current classification of DCM excludes cases in which coronary
artery disease, loading conditions, hypertension, valvular diseases
and congenital heart diseases could have caused the observed phe-
notype (Elliott et al., 2008). The exact prevalence of idiopathic
DCM varies between studies, from 1:2700 in the original epi-
demiological study (Codd et al., 1989) to 1:250 in a recent study
(Hershberger et al., 2013). PPCM, as the name implies, develops
during the last month of pregnancy, during delivery or within the
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sine kinase 1; STAT3, Signal transducer and activator of transcription 3; TTN, Gene
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first 5 months after delivery (Pearson et al., 2000). The preva-
lence of PPCM has been established to be 1:4000 to 1:1000 live
births in the Western world (Elkayam, 2011; Kolte et al., 2014),
although there is regional variation, e.g. the prevalence of PPCM
in Haiti is 1:300 live births (Fett et al., 2005). In contrast to DCM,
which typically presents later in life (Hershberger et al., 2013),
PPCM often develops in young, previously healthy women and
is a disease which progresses quickly to cardiac dysfunction and
failure as is evident in the high mortality and transplantation rate
(Van Hoeven et al., 1993; Hilfiker-Kleiner et al., 2007; Sliwa et al.,
2010; Elkayam, 2011; Fett, 2014). As symptoms of PPCM such
as dyspnea, fatigue and exercise incapacity are similar to normal
pregnancy symptoms, the disease is often diagnosed late. If diag-
nosed and treated early, women suffering from PPCM may be
stabilized upon treatment with β-blockers, ACE inhibitors and
bromocriptine (BR) and reversal of the phenotype resulting in
favorable outcome and recovery is not uncommon (Van Hoeven
et al., 1993; Felker et al., 2000; Hilfiker-Kleiner et al., 2007; Sliwa
et al., 2010; Elkayam, 2011; Ballo et al., 2012; Haghikia et al., 2013;
Fett, 2014). This is contrary to what is often observed in DCM
which is characterized by a late onset and slow disease progres-
sion that might be stabilized but unlikely to be reversed upon
treatment (Van Hoeven et al., 1993; Fish, 2012; Hershberger et al.,
2013).
PHYSIOLOGICAL ADAPTATIONS DURING PREGNANCY
The pathogenesis of PPCM is tightly bound to the cardiac
changes that accompany normal pregnancies. It is therefore
important to understand the physiological changes that occur
during pregnancy. The increased hemodynamic load caused by
the increased blood volume results in physiological hypertrophy,
in which chamber dimensions increase, concomitant with a pro-
portional increase in wall thickness to cope with the increased
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hemodynamic load and to facilitate increased cardiac output
(Clapp and Capeless, 1997; Umar et al., 2012). This physiolog-
ical hypertrophy is different from the pathological (eccentric)
hypertrophy seen in both PPCM and DCM in which chamber
dimensions increase while wall thickness does not increase pro-
portionally in response to increased hemodynamic load (Gaasch
and Zile, 2011). According to the law of Laplace this will lead to
increased wall stress. Physiological pregnancy-related hypertro-
phy is reversible post-partum, usually within 1 year after delivery
(Clapp and Capeless, 1997). Other differences between patholog-
ical and physiological hypertrophy are the absence of fibrosis and
the absence of induction of the fetal gene program in physio-
logical hypertrophy (McMullen and Jennings, 2007; Umar et al.,
2012). In addition, angiogenic factors such as vascular endothe-
lial growth factor A (VEGF A) are secreted during pregnancy
which facilitates myocardial angiogenesis in order to increase
capillary density proportionally to cardiomyocyte size. Both cap-
illary density as well as VEGF levels return to pre-pregnancy
levels post-partum (Umar et al., 2012; Chung and Leinwand,
2014). Pregnancy is often seen as a cardiac stress model upon
which underlying cardiac dysfunction may reveal itself due to the
increased hemodynamic load on the heart and hormonal changes
during pregnancy (Chung and Leinwand, 2014). However, the
increase in hemodynamic load starts early in pregnancy (Clapp
and Capeless, 1997) while PPCM develops in the last month of
pregnancy or even post-partum. It is therefore unlikely that the
increased hemodynamic load is the sole cause of PPCM.
GENETIC PREDISPOSITION AND TITIN ISOFORM
SWITCHING
As stated before, DCM can have a genetic cause, leading to
a familial form of DCM. Many mutations have been linked
to DCM. However, many of these genes are also implicated
in hypertrophic and restrictive cardiomyopathies (Hershberger
et al., 2013). A common gene which is mutated in 6% of DCM
patients is the gene encoding for the protein lamin-A/C (LMNA)
(Parks et al., 2008). LMNA mutations show a relatively high pen-
etrance compared with mutations in other genes and patients
carrying LMNA mutations often have conduction abnormalities
(Parks et al., 2008; Hershberger et al., 2013). In addition, Herman
et al. showed a high incidence of truncated variants in the gene
encoding for the protein titin (TTN) in DCM patients (Herman
et al., 2012). In PPCM, little is known about causative pathogenic
mutations. However, the fact that multiple PPCM cases within
one family have been reported (Van Spaendonck-Zwarts et al.,
2014) suggests that gene mutations could play an important role.
Furthermore, reports about DCM and PPCM cases within fam-
ilies and the identification of mutations (Morales et al., 2010;
Van Spaendonck-Zwarts et al., 2010, 2014) strengthen the sug-
gestion of a genetic cause and overlap in etiology of PPCM and
DCM. A recent study showed a high incidence of TTN variants
in PPCM patients, and this cohort was marked by slow recov-
ery (Van Spaendonck-Zwarts et al., 2014). However, it has been
proposed that TTN mutations are not always disease causing,
but might act as disease modifiers as truncated TTN variants are
present in 3% of the general population (Herman et al., 2012).
Knowledge about pathogenic effects of gene mutations would
enable the identification of persons at risk for the development
of DCM and PPCM and thereby facilitate early diagnosis and
treatment.
The protein titin acts as a multifunctional spring that can exist
as two distinct isoforms in the adult human heart; a compliant
N2BA isoform and a stiff N2B isoform. A shift to more N2BA
titin isoform and subsequent reduced passive stiffness was shown
in DCM patients previously (Makarenko et al., 2004; Nagueh
et al., 2004). Apart from isoform shift, alterations in titin post-
translational modifications such as phosphorylation are able to
alter passive force development (Granzier and Labeit, 2002). Titin
isoform has also been suggested to play a role in the ability of the
heart to adapt contractility in response to stretch, known as the
Frank-Starling mechanism (Fukuda et al., 2003). Unfortunately,
limited data is available about the role of titin in PPCM, although
increased compliant titin isoform and lowered passive tension has
been reported in one PPCM patient with a TTN mutation (Van
Spaendonck-Zwarts et al., 2014). Titin can also bemodified under
oxidizing conditions in which disulfide bridges can be formed in
titin’s N2B unique sequence possibly resulting in increased passive
stiffness (Grützner et al., 2009). In addition, S-glutathionylation
of cysteine residues in the Ig regions of titin under the influence
of redox signaling has been suggested to lower passive stiffness
(Alegre-Cebollada et al., 2014). As oxidative stress is present in
both PPCM and DCM, as described later in this review, it is pos-
sible that this will also affect titin function although this has not
been established in vivo yet.
OXIDATIVE STRESS AND PROLACTIN: A DEADLY
COMBINATION
In both DCM and PPCM, oxidative stress is a key player in dis-
ease pathogenesis. However the exact consequences of reactive
oxygen species (ROS) production differ notably between the two
disease states as will be discussed below. In normal pregnancy,
ROS production increases during the course of pregnancy and
decreases post-partum to normal levels (Toescu et al., 2002).
In an attempt to counterbalance the detrimental ROS produc-
tion, total anti-oxidant capacity also increases during pregnancy
and remains elevated post-partum (Toescu et al., 2002). In both
PPCM animal models and human PPCM patients, oxidative
stress levels are increased compared to healthy controls (Hilfiker-
Kleiner et al., 2007). An explanation for the increased oxidative
stress in PPCM can be found in the PPCM mouse model with
cardiomyocyte restricted deletion of Signal transducer and activa-
tor of transcription 3 (STAT3) (Hilfiker-Kleiner et al., 2007). This
transcription factor regulates the expression of the superoxide
scavenger Manganese superoxide dismutase (MnSOD) (Negoro
et al., 2001). Accordingly, in the cardiac STAT3 KO mice PPCM
is accompanied by a reduced expression of MnSOD and con-
comitant oxidative stress (Hilfiker-Kleiner et al., 2007). A cru-
cial pathway in PPCM that is instigated by elevated oxidative
stress is the cleavage of the hormone prolactin (PRL) by ROS-
activated Cathepsin D (CD) (Hilfiker-Kleiner et al., 2007). Upon
ROS activation CD cleaves full-length prolactin (PRL) of 23 kDa
into a smaller 16 kDa form which has detrimental effects on
cardiomyocyte metabolism and the microvasculature (Hilfiker-
Kleiner et al., 2007, 2012; Hilfiker-Kleiner and Sliwa, 2014). The
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idea that PRL plays a crucial role in PPCM is further strength-
ened by the fact that PRL levels rise at the end of pregnancy
and remain high post-partum during breast feeding which coin-
cides with the onset of PPCM (Grattan et al., 2008). Accordingly,
injection of adenoviral vectors expressing 16 kDa PRL in non-
pregnant mice led to the development of cardiac dysfunction,
dilation of the left ventricle (LV) and decreased myocardial cap-
illary density (Hilfiker-Kleiner et al., 2007). As decreased levels
of STAT3, high levels of oxidative stress, high CD activity and
16 kDa PRL have also been observed in human PPCM patients
(Hilfiker-Kleiner et al., 2007; Haghikia et al., 2013), it strength-
ens the suggestion that insufficient defense against oxidative stress
and subsequent formation of 16 kDa PRL plays an important
role in PPCM pathogenesis. The compound BR is able to inhibit
PRL release from the pituitary gland. Blockade of PRL by BR
treatment in PPCM patients has been shown to improve cardiac
function and increase survival, although only a limited number
of studies containing small patient cohorts have been performed
so far (Hilfiker-Kleiner et al., 2007; Sliwa et al., 2010; Ballo et al.,
2012; Haghikia et al., 2013). Together these results indicate that
cleavage of PRL under oxidative stress is key in the disease devel-
opment in both human PPCM as well as the cardiac STAT-3 KO
PPCMmouse-model (Hilfiker-Kleiner et al., 2007). However, not
all patients treated with BR recover (Sliwa et al., 2010; Haghikia
et al., 2013). Therefore, even though the PRL-mediated pathway
is probably a major determinant in this disease, other pathways
are likely to play a role. Since STAT3 signaling has many differ-
ent functions, it is unlikely that the repressed MnSOD expression
alone explains all observations in the STAT3 KO mouse model.
Additionally, in heterozygous MnSOD+/− mice a reduction of
MnSOD levels of 50% causes cardiac alterations under basal con-
ditions (Remmen et al., 2001) and induces cardiac remodeling
after pregnancy (Hilfiker-Kleiner et al., 2007), but it does not lead
to the dilated PPCM phenotype often seen in PPCM patients and
the cardiac STAT3 KO mouse model. This implies that besides
MnSOD additional factors are essential for the development of
PPCM.
STATs are activated upon phosphorylation by Janus kinases
(JAK) and are multifunctional transcription factors. In cardiomy-
ocytes STAT3 is involved in survival, sarcomere integrity, cell
growth and ROS production (Haghikia et al., 2014). In the vas-
culature STAT3 promotes vascularization through stimulation
of VEGF signaling (Osugi et al., 2002). Clearly STAT3 affects
multiple cardiac processes besides generation of the 16 kDa PRL
(Haghikia et al., 2014). In the cardiac STAT3 KO model, low
STAT3 levels have been associated with the up-regulation of miR-
199 (Haghikia et al., 2011). MiR-199 down-regulates specific
ubiquitin conjugating enzymes thereby affecting the ubiquitin
proteasome system (UPS). In an in vitro model, this disturbance
of the UPS resulted in decreased protein levels of myosin heavy
chain and troponin T, thereby causing disruption of sarcom-
ere structure (Haghikia et al., 2011). Also in DCM patients, low
STAT3 levels, increased miR-199 levels and decreased levels of
ubiquitin conjugating enzymes have been observed (Haghikia
et al., 2011). Low STAT3 levels have been observed in both PPCM
(Hilfiker-Kleiner et al., 2007) and DCM patients (Podewski,
2003), indicating STAT3 may be part of the common pathway of
both diseases. However, it should be noted that MnSOD protein
levels and activity have been reported to be unchanged in DCM
patients compared to non-failing controls in the myocardium
(Dieterich et al., 2000) and a higherMnSOD activity was observed
in serum (Wojciechowska et al., 2014). This indicates decreased
STAT3 levels might have different downstream effects in DCM
and PPCM and loss of MnSOD might form an etiology-specific
(additional) source of oxidative stress in PPCM.
Oxidative stress is observed in many forms of heart failure
(HF), including PPCM and DCM, and disturbs various pathways.
However, the high levels of PRL during the final stages of preg-
nancy combined with high oxidative stress, likely make PPCM
develop at such a high pace. As PRL levels are many fold lower
in non-pregnant and non-nursing individuals (Grattan et al.,
2008), it is unlikely that PRL also plays a role in DCM patients.
Although oxidative stress has many detrimental effects in the fail-
ing heart it should be noted that ROS also fulfill a beneficial role
in physiological circumstances. For example, NADPH oxidase
(NOXs) produce ROS in a tightly regulated manner and play an
important role in stretch-induced contraction by sensitization of
the ryanodine receptor (RyR2) through oxidation (Prosser et al.,
2011). However, in DCM NOX activity is up-regulated leading
to increased ROS production (Maack et al., 2003). Amongst oth-
ers oxidative stress inactivates important ion channels such as the
L-type-calcium channel (LTCC) and the sarcoendoplasmic retic-
ulum calcium transport ATPase (SERCA2a) and, in combination
with disturbed RyR2 sensitization, may lead to Ca2+ depletion
from the sarcoplasmic reticulum (Sag et al., 2013). Another gen-
eral feature of HF is elevated cytosolic Na+ levels (Despa, 2002)
that result in decreased Ca2+ uptake and consequently reduced
NADPH generation in mitochondria [28]. This disturbed balance
of ions within cardiomyocytes causes cardiac dysfunction due to
disturbed excitation-contraction coupling (Sag et al., 2013). In
turn reduced mitochondrial NADPH availability leads to reduced
generation of mitochondrial antioxidants and increased levels of
ROS (Kohlhaas et al., 2010). In addition, ROS causes NADPH
oxidation, thereby further reducing NADPH bioavailability for
the production of ROS scavenger enzymes. In addition, ROS
can reduce the bioavailability of tetrahydrobiopterin (BH4) and
thereby induce the uncoupling of nitric oxide synthase (NOS).
As a result NOS no longer produces beneficial nitric oxide (NO)
molecules, but itself becomes a producer of superoxide (Verhaar,
2004). In this way ROS production can be self-sustaining and
cause additional ROS production (Seddon et al., 2007) thereby
locking the heart in a vicious circle of oxidative stress (Kohlhaas
et al., 2010). Similarly the NOS inhibitor asymmetric dimethy-
larginine (ADMA), a factor shown to be up-regulated in both
DCM and PPCM and described later in this review, has been
suggested to stimulate NOS-uncoupling mediated ROS produc-
tion (Wilcox, 2012). However, it should be noted that ADMA
levels at expected pathological concentrations only had modest
effect on ROS production in this study (Druhan et al., 2008). The
vicious circle of ROS production amplification and Na+/Ca2+
imbalance can be visualized in Figure 1. Apart from affecting
cardiomyocyte ion balance, ROS has many other detrimental
effects on cardiomyocytes such as nitration of creatine kinase,
SERCA2a, voltage gated K+ channels, desmin, myosin heavy
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chain and α-actinin, induction of DNA damage, cell death and
fibrosis (Pacher et al., 2007; Seddon et al., 2007). As fibrosis can
increase myocardial stiffness and does not contribute to active
force development, increased fibrosis can influence both systolic
and diastolic function. Increased fibrosis is common in DCM
patients (Assomull et al., 2006; Herpel et al., 2006) and the car-
diac STAT3 KOmouse model of PPCM (Ricke-Hoch et al., 2014),
however, there are limited and contradictory reports about fibro-
sis in PPCM patients (Kawano et al., 2008; Mouquet et al., 2008;
Leurent et al., 2009; Ntusi and Chin, 2009).
Together, alterations induced by ROS can lead to cardiomy-
ocyte dysfunction through impaired Na+ and Ca2+ handling,
impaired sarcomere integrity, cardiomyocyte death and fibrosis
formation. Although 16 kDa PRL is an important contributor to
the pathophysiology of PPCM, it is likely that oxidative stress-
induced cardiac pathology in PPCM also involve other ROS
induced pathways.
DISTURBED SARCOMERE INTEGRITY AND ANGIOGENIC
IMBALANCE
The previously described disturbance in the ubiquitin protea-
some system (UPS) system also leads to increased levels of ADMA
(Haghikia et al., 2011), a factor involved in reducing NO avail-
ability by competing with the NOS substrate L-arginine, and
increasing ROS production by endothelial cells thereby contribut-
ing to the amplification of ROS production and cardiac dysfunc-
tion shown in Figure 1 (Druhan et al., 2008). Also in human
PPCM (Haghikia et al., 2013) and DCM patients increased
levels of ADMA have been found and in DCM decreased L-
arginine/ADMA ratio was shown to be a predictor of mortality
(Anderssohn et al., 2012). The male mice of the cardiac STAT3
KO model showed age-related loss of capillary density and a
DCM-like phenotype upon aging including fibrosis and impaired
sarcomere organization (Hilfiker-Kleiner et al., 2004). Several
studies indicate that damaged microvasculature or disturbance in
FIGURE 1 | Disturbed Na+/Ca2+ signaling and ROS production can be locked in a vicious circle in heart failure. Red boxes indicate down-regulated or
disturbed factors; green boxes indicate up-regulated factors in disease.
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pro- and anti-angiogenic factors play a significant role in PPCM
pathogenesis. A study by Patten et al. showed a high prevalence
(33%) of (pre)eclampsia in their PPCM cohort (Patten et al.,
2012), which is believed to be a risk factor for PPCM. It has been
shown that PPCM leads to capillary dissociation and endothelial
cell apoptosis (Hilfiker-Kleiner et al., 2007). Patten et al. suggested
that the anti-angiogenic state might worsen the severity of the
disease (Patten et al., 2012). In late pregnancy, anti-angiogenic
factors, such as soluble, fms-like tyrosine kinase 1 (sFLT1), are
secreted and thereby inhibit the increased VEGF signaling dur-
ing pregnancy (Chung and Leinwand, 2014). The increase in
anti-angiogenic factors is significantly higher in patients with
(pre)eclampsia which results in decreased VEGF levels (Levine
et al., 2004) and also unusually high levels of sFLT1 have been
observed in PPCM patients (Patten et al., 2012). This indicates
the anti-angiogenic state is important in both (pre)eclampsia
and PPCM pathogenesis and might explain the high prevalence
of (pre)eclampsia among PPCM patients. A common finding
in PPCM studies is a reduced capillary density in the post-
partum phase (Hilfiker-Kleiner et al., 2007; Patten et al., 2012).
Disturbed VEGF signaling and decreased capillary density have
also been observed in DCM (Abraham et al., 2000; Karch et al.,
2005; Lionetti et al., 2014). Another KO mouse model which
lacks the cardiac PPARγ coactivator-1α (PGC-1α), also results
in the development of PPCM (Patten et al., 2012). PGC-1α pro-
motes angiogenesis by stimulating VEGF signaling (Arany et al.,
2008; Patten et al., 2012), (cardiac) mitochondrial biogenesis and
metabolism in a tissue specific manner (Lehman et al., 2000;
Arany et al., 2005). However, also in this model PPCM develop-
ment occurs through the MnSOD, ROS and 16 kDa PRL pathway
as the phenotype could only be partly rescued by pro-angiogenic
therapy in the form of VEGF A and treatment with both VEGF
A and BR was needed to obtain full recovery of LV function.
Indeed, in PGC-1α KO mice MnSOD was reduced and ROS
increased, which is not surprising as PGC-1α is an inducer of
MnSOD (Patten et al., 2012). Repressed levels of PGC-1α have
also been observed in PPCM patients (Patten et al., 2012). PGC-
1α could also be implied in DCM as PGC-1α KO mice showed
inability to increase heart rate in response to dobutamine, had
markedly depressed levels of ATP in cardiac muscle and showed
ventricle dilation and reduced fractional shortening upon aging
(7–8 months), indicating PGC-1α deficiency can induce a DCM-
like phenotype (Arany et al., 2005). However, depressed levels
of PGC-1α-regulated genes, but not expression levels of PGC-
1α itself, have been reported in DCM (Sihag et al., 2009). The
extend of depression of PGC-1α regulated genes has been shown
to be correlated to LV systolic function, which indicate mito-
chondrial function as regulated by PGC-1α is impaired in HF
(Sihag et al., 2009). The 16 kDa PRL increases NFκB activity
induced by miR-146 and thereby causes endothelial cell apoptosis
(Tabruyn et al., 2003; Halkein et al., 2013). In addition, 16 kDa
PRL up-regulates exosome loading with miR-146 of endothelial
cells. Uptake of these exosomes by cardiomyocytes causes miR-
146 induced impaired metabolic activity (Halkein et al., 2013).
An interesting notion is that miR-146 has been shown to be up-
regulated in PPCM but not in DCM patients (Haghikia et al.,
2013; Halkein et al., 2013). This indicates that although both
patient groups suffer from dysfunctional microvasculature, the
exact underlying pathogenesis might not be the same. Impaired
microvasculature may result in insufficient oxygen and nutrient
delivery to cardiomyocytes resulting in increased susceptibility to
apoptosis and impaired cardiac function. It is clear that PPCM
and DCM can result in similar clinical presentation even without
the presence of PRL. The cleaved form of PRL is likely to cause
an additional hit in PPCM quickly worsening disease progression
and outcome. An overview of the changes in PPCM and DCM
compared to healthy controls, grouped by downstream effect, can
be seen in Table 1.
PREGNANCY IN DCM PATIENTS AND SUBSEQUENT
PREGNANCIES IN PPCM PATIENTS
Given the similarities between PPCM and DCM, DCM patients
presenting with the wish to conceive are a complicated patient
group to counsel. Only a few studies have explored the dis-
ease alterations in DCM patients who become pregnant. The
effects of pregnancy on cardiac function in DCM patients are
contradictory as limited adverse events and recovery toward pre-
pregnancy cardiac function (Bernstein and Magriples, 2001; Blatt
et al., 2010), but also significant decreased cardiac event-free
survival compared to non-pregnant DCM patients has been
reported (Grewal et al., 2009). Adverse outcome in pregnant
DCM patients was related to high NTproBNP levels, a known
indicator for cardiac dysfunction, Blatt et al. (2010) and New
York Heart Association functional classification class III or IV
(Grewal et al., 2009). Most cardiac adverse events occurred at
the beginning of the third trimester, which coincided with an
increase in hemodynamic load on the heart (Grewal et al., 2009)
Table 1 | Altered parameters in PPCM and DCM compared to healthy
controls.
Parameter PPCM DCM
Structure Chamber dilation ↑ ↑
Sarcomere mutations Possible Possible
Sarcomere integrity ↓ ↓
Fibrosis ↑ in animals,
unknown in human
↑
Fetal gene program Unknown ↑
Titin N2BA/N2B ratio Unknown ↑
Oxidative stress Oxidative stress ↑ ↑
MnSOD ↓ =
16 kDa PRL ↑ Unlikely
PGC-1α ↓ ↓ target gene
expression
STAT3 ↓ ↓





References for the shown parameters are indicated in the text.
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while PRL levels are still relatively low. Another case report that
showed adverse events during pregnancy in a DCM patient also
showed adverse events earlier in pregnancy than is observed in
PPCM (Gevaert et al., 2014). Therefore, most adverse events seen
in pregnant DCM patients are most likely due to the cardiac
stress during pregnancy that is being placed on an already trou-
bled heart. However, most adverse events were successfully treated
and recovery to pre-pregnancy cardiac function was often estab-
lished. A retrospective study by Bernstein et al. showed pregnancy
is well-tolerated in stable DCM patients, while maternal out-
come was significantly worse in PPCM patients (Bernstein and
Magriples, 2001). Therefore, Bernstein et al. suggest the progno-
sis of PPCM patients should not be used when a stable DCM
patient presents herself with the wish to conceive (Bernstein and
Magriples, 2001). This strengthens the suggestion that although
PPCM and DCM may share similar genetic predispositions and
some common disease pathways, PPCM should not be considered
as DCM occurring during or soon after pregnancy. However, it is
also possible that pregnant DCM patients are protected from the
fast deterioration of cardiac function seen in PPCM due to the
fact that DCM patients are already treated for heart failure prior
to and during pregnancy and are closely monitored. A small study
by Hilfiker-Kleiner et al. showed BR treatment of PPCM patients
in their subsequent pregnancy was able to improve survival and
prevent relapse compared to PPCM patients without BR treat-
ment (Hilfiker-Kleiner et al., 2007). Studies exploring subsequent
pregnancies of PPCM patients revealed a HF relapse in 20–30%
and the ability to recover was related to cardiac function after
PPCM index pregnancy and prior to the subsequent pregnancy
(Elkayam et al., 2005; Fett et al., 2010). From these studies it can
be concluded that stable DCM patients are unlikely to develop
the fast PPCM disease progression and that the outcome of the
DCM patient group is often more favorable than that of PPCM
patients. The potential uneventful previous and subsequent preg-
nancies in PPCM patients indicate we do not know all triggers
of PPCM since any predisposing mutation and PRL would also
have been present in previous and subsequent event-free preg-
nancies. As PRL is present in both pregnant DCM patients and
PPCM patients, we cannot simply state that PPCM is triggered by
the presence of PRL in combination with a weakened heart.
FUTURE PERSPECTIVES
LARGE COHORT STUDIES PPCM
At the moment there is still a lack of prospective studies explor-
ing PPCM in larger cohorts. Most studies to date are case studies
or small (often retrospective) cohort studies. A large, multicenter,
randomized controlled clinical trial to evaluate BR treatment in
60 PPCM patients is ongoing, and the results should shed light
on the effectiveness of BR treatment and outcome (US National
Library of Medicine, 2012). In addition, the EURObservational
Registry on PPCM has started to enroll patients that will be fol-
lowed in a 1-year prospective study which will help to evaluate
PPCM clinical presentations, risk factors, management and the
effects on offspring worldwide (Sliwa et al., 2014).
GENETIC PREDISPOSITIONS
Information about disease initiation and predispositions such
as pathogenic mutations is still limited in PPCM and DCM.
Therefore, more knowledge is needed on which mutations pre-
dispose people to DCM and PPCM and how these mutations
exert their pathogenic effect in disease initiation and progression.
Identification of these mutations would greatly enhance the abil-
ity to identify persons at risk to develop PPCM and DCM and by
monitoring these patients early diagnosis and treatment could be
facilitated thereby enhancing survival.
CARDIAC REMODELING
As cardiac deterioration, heart transplantations and death often
occur within a few months after diagnosis in PPCM, it is pos-
sible that the cardiac remodeling to cope with the new cardiac
state and demands in PPCM is different than in a more slow
progressive disease as DCM. For example, in heart failure it has
been shown that the fetal gene program is initiated resulting in
cardiac remodeling in order to compensate for decreased car-
diac function, although it contributes to cardiac dysfunction at
a later stage (Thum et al., 2007). The limited time for adaptation
of the heart might be detrimental in PPCM patients, as the lack
of time to mount a compensatory response causes the need for
cardiac transplantation, or lead to death soon after diagnosis. On
the other hand, full recovery of PPCM patients may be explained
by lack of permanent cardiac remodeling. However, not enough
is known about remodeling of the PPCM heart and the recom-
mendation to not use gadolinium in pregnant women has limited
the use of magnetic resonance imaging (MRI) to assess fibrosis
in PPCM patients. Therefore, other techniques to assess cardiac
remodeling such as immunohistochemical staining of biopsies or
explanted heart tissue should be explored in order to shed light
on cardiac remodeling in PPCM.
OXIDATIVE STRESS
Based on observations in the STAT3 mouse model, mitigation
of the intracellular defense mechanism against oxidative stress in
human PPCM so far mainly focused on the reduction of MnSOD
levels. Indeed reduction of MnSOD levels is an important con-
tributor to elevated ROS levels in PPCM patients. However,
to further unravel the patho-mechanism of oxidative stress in
PPCM, future studies should involve the potential contribution
of other enzymatic and non-enzymatic ROS scavengers as well as
that of potential sources of ROS. ReducedMnSOD expression and
PRL cleavage as a result of concomitant oxidative stress have been
identified as important regulators of PPCM. Still the complete
etiology of PPCM is far from completely understood.
SUMMARY AND CONCLUSION
PPCM and DCM likely share part of their pathogenesis such as
predisposing mutations, increased oxidative stress, an impaired
microvasculature and damaged sarcomere integrity. However, the
exact underlying pathways might be differently altered in PPCM
and DCM. While 16 kDa PRL is likely to be a key player in
PPCM it is unlikely to play a significant role in DCM. It is
this 16 kDa PRL that might explain the faster deterioration of
cardiac function in PPCM by inducing an additional cascade
of cardiovascular impairment. However, given the observation
that pregnant DCM patients do better than PPCM patients,
this difference in PRL levels between PPCM patients and non-
pregnant DCM patients cannot explain all differences observed.
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The reports about uneventful subsequent pregnancies in PPCM
patients indicate additional causative factors, such as insuffi-
cient defense mechanisms against oxidative stress or a vulnerable
microvasculature. Therefore, despite their overlap in disease etiol-
ogy and clinical presentation, differences in underlying pathways,
disease progression and outcome argue for separation of the two
disease states.
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